<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37213031</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1335</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of cancer research and clinical oncology</Title><ISOAbbreviation>J Cancer Res Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis.</ArticleTitle><Pagination><StartPage>9517</StartPage><EndPage>9528</EndPage><MedlinePgn>9517-9528</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-023-04853-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current observational studies suggest that there may be a causal relationship between systemic lupus erythematosus (SLE) and prostate cancer (PC). However, there is contradictory evidence. This study aimed to investigate and clarify the association between SLE and PC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed, Embase, Web of Science, and Scopus until May 2022. A meta-analysis was conducted on the standard incidence rate (SIR) and 95% CI. Subgroup analysis was performed based on the follow-up duration, study quality, and appropriate SLE diagnosis. Mendelian randomization (MR) of the two samples was used to determine whether genetically elevated SLE was causal for PC. Summary MR data were obtained from published GWASs, which included 1,959,032 individuals. The results were subjected to sensitivity analysis to verify their reliability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a meta-analysis of 79,316 participants from 14 trials, we discovered that patients with SLE had decreased PC risk (SIR, 0.78; 95% CI, 0.70-0.87) significantly. The MR results showed that a one-SD increase in genetic susceptibility to SLE significantly reduced PC risk (OR, 0.9829; 95% CI, 0.9715-0.9943; P&#x2009;=&#x2009;0.003). Additional MR analyses suggested that the use of immunosuppressants (ISs) (OR, 1.1073; 95% CI, 1.0538-1.1634; P&#x2009;&lt;&#x2009;0.001), but not glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs), which were associated with increased PC risk. The results of the sensitivity analyses were stable, and there was no evidence of directional pleiotropy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that patients with SLE have a lower risk of developing PC. Additional MR analyses indicated that genetic susceptibility to the use of ISs, but not GCs or NSAIDs, was associated with increased PC risk. This finding enriches our understanding of the potential risk factors for PC in patients with SLE. Further study is required to reach more definitive conclusions regarding these mechanisms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Junyong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhen</LastName><ForeName>Kailan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yaqian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Zixuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yangyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiming</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Lulin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, Peking University Third Hospital, Peking University Health Science Center, 49 North Garden Road, Beijing, 100191, China. chengliu@bjmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Shanghai, 200080, China. chengliu@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81972381</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82070778</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cancer Res Clin Oncol</MedlineTA><NlmUniqueID>7902060</NlmUniqueID><ISSNLinking>0171-5216</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic variants</Keyword><Keyword MajorTopicYN="N">Genome-wide association studies</Keyword><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">Prostate cancer</Keyword><Keyword MajorTopicYN="N">Risk</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37213031</ArticleId><ArticleId IdType="pmc">PMC10423167</ArticleId><ArticleId IdType="doi">10.1007/s00432-023-04853-5</ArticleId><ArticleId IdType="pii">10.1007/s00432-023-04853-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alarc&#xf3;n-Segovia D, P&#xe9;rez-V&#xe1;zquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21(5):275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">1604324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao HH, Chuan JS, Han J, Shui CQ, Bin DC, Ming PC. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol. 2014;140(7):1067&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">24525705</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin North Am. 2017;101(4):787&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">28577627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47(12):1457&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun. 2013;42:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646904</ArticleId><ArticleId IdType="pubmed">23410586</ArticleId></ArticleIdList></Reference><Reference><Citation>Berndt SI, Gustafsson S, M&#xe4;gi R, Ganna A, Wheeler E, Feitosa MF, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45(5):501&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973018</ArticleId><ArticleId IdType="pubmed">23563607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rn&#xe5;dal L, L&#xf6;fstr&#xf6;m B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12109649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel Rl, La Torre, Jemal A. 2018 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 68(6). Available from: https://pubmed.ncbi.nlm.nih.gov/30207593/</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu H, Narisu N, Schlick B, Rainer J, Manke T, Sch&#xe4;fer G, et al. Putative prostate cancer risk snp in an androgen receptor-binding site of the melanophilin gene illustrates enrichment of risk snps in androgen receptor target sites. Hum Mutat. 2016;37(1):52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715509</ArticleId><ArticleId IdType="pubmed">26411452</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S. Sample size and power calculations in mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43(3):922&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052137</ArticleId><ArticleId IdType="pubmed">24608958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Tong H, Xu G, Liu P, Meng H, Wang J, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS ONE. 2015;10(4):e0122964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401738</ArticleId><ArticleId IdType="pubmed">25885411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Chang YT, Wang CB, Wu CY. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010;123(12):1150.e1&#x2013;1150.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21183006</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001;10(6):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">11434573</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey D, Kenu E, Isenberg D. Cancer complicating systemic lupus erythematosus &#x2013; a dichotomy emerging from a nested case-control study. Lupus. 2013;22(9):919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107831</ArticleId><ArticleId IdType="pubmed">23857987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">30131606</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: A long-term followup study in a Danish cohort: Cancer in SLE. Arthritis Rheum. 2011;63(10):3032&#x2013;3037.</Citation><ArticleIdList><ArticleId IdType="pubmed">21953088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">10028970</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh LM, Huang E, Towe M, Liang K, El Khatib FM, Yafi FA, et al. Evidence for the integration of total and free testosterone levels in the management of prostate cancer. BJU Int. 2021;130:76.</Citation><ArticleIdList><ArticleId IdType="pubmed">34716982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiwata T, Matsuda Y, Naito Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol. 2011;17(4):409&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3027007</ArticleId><ArticleId IdType="pubmed">21274370</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Wel&#xe9;n K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010;17(2):469&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008;72(6):1240&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">18692874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Chu H, Murad MH, Hong C, Qu Z, Cole SR, et al. Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med. 2018;33(8):1260&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082203</ArticleId><ArticleId IdType="pubmed">29663281</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Ji J, Forsti A, Sundquist K, Sundquist J, Hemminki K. Autoimmune disease and subsequent urological cancer. J Urol. 2013;189(6):2262&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pubmed">23228387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao S, Shen H, Zhang J. Systemic lupus erythematosus and malignancies risk. J Cancer Res Clin Oncol. 2016;142(1):253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">26319223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellemkj&#xe9;r L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin&#x2019;s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(4):761&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus. 2000;9(4):252&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10866095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nived O, Bengtsson A, Jo&#xc8;nsen A, Sturfelt G, Olsson H. 2023 Malignancies during follow-up in an epidemiologically de&#xae;ned systemic lupus erythematosus inception cohort in southern Sweden. 5</Citation><ArticleIdList><ArticleId IdType="pubmed">11480849</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, Pillinger MH, et al. Sex Differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020;95(2):384&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">32029091</ArticleId></ArticleIdList></Reference><Reference><Citation>Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6):1021&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113751</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008;19(8):887&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357418</ArticleId><ArticleId IdType="pubmed">18386139</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A. Does baseline serum testosterone influence androgen deprivation therapy outcomes in hormone na&#xef;ve patients with advanced prostate cancer? J Urol. 2021;205(3):806&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">33035140</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">19198622</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280714</ArticleId><ArticleId IdType="pubmed">29311132</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. Cancer Lett. 1997;111(1):221&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9022150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in lobund wistar rats by testosterone. Prostate. 1982;3(6):563&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">7155989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragnarsson O, Grondal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus. 2003;12(9):687&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">14514131</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ et al. 2018 Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet [Internet]. 50(7). Available from: https://pubmed.ncbi.nlm.nih.gov/29892016/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568012</ArticleId><ArticleId IdType="pubmed">29892016</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology. 2000;39(10):1147&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallbacka K, Pettersson T, Pukkala E. Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. Scand J Rheumatol. 2018;47(6):461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">29318934</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, TchetgenTchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiol Camb Mass. 2014;25(3):427&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981897</ArticleId><ArticleId IdType="pubmed">24681576</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol. 2018;74(5):585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195673</ArticleId><ArticleId IdType="pubmed">30077399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, et al. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):167&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">17199135</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann R, Zobbe K, Cordtz R, Haugaard JH, Dreyer L. Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: A danish nationwide cohort study. Lupus. 2021;30(5):752&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">33497306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WCW, Cheung CSK, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol. 2008;17(5):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603000</ArticleId><ArticleId IdType="pubmed">19014686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Wang W, Xu J, Zhang MS, Mei H, Shen Y, et al. Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus. Ann Transl Med. 2019;7(5):93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6462640</ArticleId><ArticleId IdType="pubmed">31019943</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo J, Seo MS, Hwang IC, Shim JY. An updated meta-analysis on the risk of urologic cancer in patients with systemic lupus erythematosus. Arch Iran Med. 2020;23(9):614&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">32979908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>